Considerations for the successful co-development of targeted cancer therapies and companion diagnostics

被引：0

作者：

Jane Fridlyand

Richard M. Simon

Jessica C. Walrath

Nancy Roach

Richard Buller

David P. Schenkein

Keith T. Flaherty

Jeff D. Allen

Ellen V. Sigal

Howard I. Scher

机构：

[1] Genentech,

[2] US National Cancer Institute,undefined

[3] Friends of Cancer Research,undefined

[4] Fight Colorectal Cancer,undefined

[5] Pfizer,undefined

[6] 10555 Science Center Drive,undefined

[7] Agios Pharmaceuticals,undefined

[8] Massachusetts General Hospital,undefined

[9] Memorial Sloan-Kettering Cancer Center,undefined

来源：

Nature Reviews Drug Discovery | 2013年 / 12卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Here, the authors discuss issues relating to the co-development of targeted cancer therapies and companion diagnostics that were not covered in depth in the draft guidance released by the US Food and Drug Administration in 2011. They propose potential strategies that will be useful to mitigate challenges and to help guide the future co-development of drugs and diagnostics.

引用

页码：743 / 755

页数：12

共 50 条

[1] Considerations for the successful co-development of targeted cancer therapies and companion diagnostics
Fridlyand, Jane
Simon, Richard M.
Walrath, Jessica C.
Roach, Nancy
Buller, Richard
Schenkein, David P.
Flaherty, Keith T.
Allen, Jeff D.
Sigal, Ellen V.
Scher, Howard I.
[J]. NATURE REVIEWS DRUG DISCOVERY, 2013, 12 (10) : 743 - 755
[2] Co-development of a companion diagnostic for targeted cancer therapy
Cheng, Suzanne
Koch, Walter H.
Wu, Lin
[J]. NEW BIOTECHNOLOGY, 2012, 29 (06) : 682 - 688
[3] The role of companion diagnostics in the development and use of mutation-targeted cancer therapies
Papadopoulos, Nickolas
Kinzler, Kenneth W.
Vogelstein, Bert
[J]. NATURE BIOTECHNOLOGY, 2006, 24 (08) : 985 - 995
[4] The role of companion diagnostics in the development and use of mutation-targeted cancer therapies
Nickolas Papadopoulos
Kenneth W Kinzler
Bert Vogelstein
[J]. Nature Biotechnology, 2006, 24 : 985 - 995
[5] Targeted therapies with companion diagnostics in the management of breast cancer: current perspectives
Myers, Meagan B.
[J]. PHARMACOGENOMICS & PERSONALIZED MEDICINE, 2016, 9 : 7 - 16
[6] A two-stage Bayesian design for co-development of new drugs and companion diagnostics
Karuri, Stella Wanjugu
Simon, Richard
[J]. STATISTICS IN MEDICINE, 2012, 31 (10) : 901 - 914
[7] A Systems Evaluation Model for the Development of Companion Diagnostics and Associated Molecularly Targeted Therapies
Okamura, Kozue
Tsuchiya, Hiroki
Hamada, Risa
Hayashi, Yusuke
Badr, Sara
Ohta, Seiichi
Sugiyama, Hirokazu
[J]. JOURNAL OF PHARMACEUTICAL INNOVATION, 2023, 18 (04) : 2265 - 2276
[8] A Systems Evaluation Model for the Development of Companion Diagnostics and Associated Molecularly Targeted Therapies
Kozue Okamura
Hiroki Tsuchiya
Risa Hamada
Yusuke Hayashi
Sara Badr
Seiichi Ohta
Hirokazu Sugiyama
[J]. Journal of Pharmaceutical Innovation, 2023, 18 : 2265 - 2276
[9] Co-development of diagnostic vectors to support targeted therapies and theranostics: essential tools in personalized cancer therapy
Nicolaides, Nicholas C.
O'Shannessy, Daniel J.
Albone, Earl
Grasso, Luigi
[J]. FRONTIERS IN ONCOLOGY, 2014, 4
[10] Co-development project for companion diagnostic announced
Crews, Kasumi
[J]. BIOANALYSIS, 2014, 6 (03) : 278 - 278

← 1 2 3 4 5 →